Breast cancer drug ineffective in treating squamous non-small cell lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Martin Edelman, chair of hematology and oncology at Fox Chase Cancer Center, presented the results of a clinical study testing palbociclib, a drug used to treat breast cancer, in patients with squamous non-small cell lung cancer at the American Society of Clinical Oncology.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

A recent OncoHost study provides insight in understanding resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer. Through a comprehensive bioinformatic analysis of pretreatment plasma proteomic profiles from 272 NSCLC patients, researchers identified key biological processes associated with resistance and revealed therapeutic targets that could inform future precision treatment strategies.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login